Elizabeth E Reed Travere Therapeutics, Inc. (TVTX) insider trading activity

Elizabeth E Reed is SVP, GC & CORPORATE SECRETARY of Travere Therapeutics, Inc.. Currently has a direct ownership of 78,633 shares of TVTX, which is worth approximately $1.2 Million. The most recent transaction as insider was on Sep 09, 2024, when has been sold 4,387 shares (Common Stock) at a price of $11.52 per share, resulting in proceeds of $50,538. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 78.6K

3.1% 3M change

35.35% 12M change

Total Value Held $1.2 Million

ELIZABETH E REED Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 09 2024	SELL Open market or private sale	$50,538 $11.52 p/Share	4,387 Reduced 5.28%	78,633 Common Stock
Sep 05 2024	BUY Grant, award, or other acquisition	-	6,750 Added 7.52%	83,020 Common Stock
Feb 01 2024	SELL Open market or private sale	$41,446 $8.7 p/Share	4,764 Reduced 5.88%	76,270 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	25,000 Added 23.58%	81,034 Common Stock
Jan 23 2024	SELL Open market or private sale	$18,475 $8.96 p/Share	2,062 Reduced 3.55%	56,034 Common Stock
Sep 05 2023	SELL Open market or private sale	$26,698 $14.71 p/Share	1,815 Reduced 3.03%	58,096 Common Stock
Aug 31 2023	BUY Grant, award, or other acquisition	-	3,300 Added 5.22%	59,911 Common Stock
May 10 2023	SELL Open market or private sale	$13,686 $16.59 p/Share	825 Reduced 1.44%	56,611 Common Stock
Feb 01 2023	SELL Open market or private sale	$57,627 $22.25 p/Share	2,590 Reduced 4.31%	57,436 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	20,250 Added 25.23%	60,026 Common Stock
Jan 24 2023	SELL Open market or private sale	$44,333 $21.5 p/Share	2,062 Reduced 4.93%	39,776 Common Stock
May 12 2022	SELL Open market or private sale	$22,586 $21.51 p/Share	1,050 Reduced 2.45%	41,838 Common Stock
May 10 2022	SELL Open market or private sale	$19,359 $21.51 p/Share	900 Reduced 2.06%	42,888 Common Stock
Jan 31 2022	SELL Open market or private sale	$36,990 $27.4 p/Share	1,350 Reduced 2.99%	43,788 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	9,840 Added 17.9%	45,138 Common Stock
Jan 24 2022	SELL Open market or private sale	$56,205 $24.98 p/Share	2,250 Reduced 5.99%	35,298 Common Stock
Jan 11 2022	SELL Open market or private sale	$137,000 $27.4 p/Share	5,000 Reduced 11.75%	37,548 Common Stock
Jan 10 2022	BUY Grant, award, or other acquisition	-	5,000 Added 10.52%	42,548 Common Stock
Aug 17 2021	SELL Open market or private sale	$24,088 $17.12 p/Share	1,407 Reduced 3.61%	37,548 Common Stock
Aug 13 2021	BUY Grant, award, or other acquisition	-	4,500 Added 10.36%	38,955 Common Stock
May 12 2021	SELL Open market or private sale	$31,622 $19.46 p/Share	1,625 Reduced 4.5%	34,455 Common Stock
May 11 2021	SELL Open market or private sale	$31,102 $19.14 p/Share	1,625 Reduced 4.31%	36,080 Common Stock
Feb 08 2021	SELL Open market or private sale	$71,055 $31.58 p/Share	2,250 Reduced 5.63%	37,705 Common Stock
Feb 05 2021	SELL Open market or private sale	$70,672 $31.41 p/Share	2,250 Reduced 5.33%	39,955 Common Stock
Feb 03 2021	SELL Open market or private sale	$91,789 $28.91 p/Share	3,175 Reduced 7.77%	37,705 Common Stock

EER

Elizabeth E Reed

SVP, GC & CORPORATE SECRETARY

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account